首页> 外文期刊>Pharmacology, Biochemistry and Behavior >The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling
【24h】

The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling

机译:mGluR7变构激动剂AMN082通过调节谷氨酸能信号传导产生抗抑郁样作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Currently prescribed antidepressants affect the reuptake and/or metabolism of biogenic amines. Unfortunately for patients, these treatments require several weeks to produce significant symptom remission. However, recently it has been found that ketamine, a dissociative anesthetic agent that noncompetitively antagonizes NMDA (N-Methyl-d-aspartic acid) receptors, has rapid antidepressant effects at sub-anesthetic doses in clinically depressed patients. These findings indicate that modulation of the glutamatergic system could be an efficient way to achieve antidepressant activity. For this reason, other mechanisms influencing glutamatergic functioning have gained interest. For example, the metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 (N,N′-dibenzyhydryl-ethane-1,2-diamine dihydrochloride) has been shown to be effective in the forced swim and tail-suspension test, behavioral assays sensitive to antidepressants. Here we extend the characterization of AMN082 by demonstrating its effects on differential reinforcement of low rates of responding (DRL)-30, another assay sensitive to antidepressants. Furthermore, we show the engagement of glutamatergic signaling by demonstrating the ability of the selective AMPA (2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid) receptor antagonist NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline- 2,3-dione) to reverse the effects of AMN082 in the tail suspension test. In contrast, NBQX failed to reverse the effects of imipramine in the same behavioral test. Finally, we report that behaviorally efficacious doses of AMN082 modulate phosphorylation of AMPA and NMDA receptor subunits in the hippocampus. These results suggest that the antidepressant-like effects of AMN082 are, at least in part, due to modulation of AMPA and NMDA receptor activity. Therefore, our findings confirm the hypothesis that mGluR7 could represent a novel target for treating depression.
机译:当前处方的抗抑郁药影响生物胺的再摄取和/或代谢。不幸的是,对于患者而言,这些治疗需要数周时间才能产生明显的症状缓解。然而,最近发现,氯胺酮是一种非竞争性拮抗NMDA(N-甲基-d-天冬氨酸)受体的解离性麻醉剂,在临床上抑郁的患者中,亚麻醉剂量具有快速的抗抑郁作用。这些发现表明,调节谷氨酸能系统可能是实现抗抑郁活性的有效方法。因此,影响谷氨酸能功能的其他机制引起了人们的兴趣。例如,已证明代谢型谷氨酸受体7(mGluR7)变构激动剂AMN082(N,N'-二苯甲酰基-乙烷-1,2-二胺二盐酸盐)在强迫游泳和尾部悬吊试验中有效,行为分析敏感抗抑郁药。在这里,我们通过证明AMN082对低响应率(DRL)-30的差异增强的影响来扩展AMN082的表征,DRK-30对抗抑郁药敏感。此外,我们通过展示选择性AMPA(2-氨基-3-(5-甲基-3-氧代-1,2,-恶唑-4-基)丙酸)受体拮抗剂NBQX( 2,3-二羟基-6-硝基-7-氨磺酰基-苯并[f]喹喔啉-2,3-二酮)可逆转AMN082在尾部悬架测试中的作用。相反,在同一行为测试中,NBQX无法逆转丙咪嗪的作用。最后,我们报告行为有效剂量的AMN082调节海马AMPA和NMDA受体亚基的磷酸化。这些结果表明,AMN082的抗抑郁样作用至少部分是由于对AMPA和NMDA受体活性的调节。因此,我们的发现证实了mGluR7可以代表治疗抑郁症的新目标这一假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号